Shivaani Kummar

21PUBLICATIONS
189CO-AUTHORS
Molecular targetsMedical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jun 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.

|May 18, 2026
Lipid Nanoparticle-Encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ plus Durvalumab Induces an Immunostimulatory Effect within the Tumor Microenvironment in Patients with Advanced Solid Tumors.

|Mar 27, 2026
CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts Anti-PD-1 Efficacy in Transgenic Mammary Tumors.

Amanda Poissonnier, Hope S Rugo, Wesley Horton

|Jul 16, 2025
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors.

Geraldine O'Sullivan Coyne, Khanh T Do, Shivaani Kummar

|May 16, 2025
Response to a novel type II RAF inhibitor in diffuse leptomeningeal glioneuronal tumor with BRAF fusion.

Brie M Chun, Sandra Youngworth, Vicki Abtin

|Mar 19, 2025
A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors.

Sarah J Shin, Geraldine O'Sullivan Coyne, Shivaani Kummar

Pageof 4

Frequent Collaborators

3 joint publications

Geraldine O'Sullivan Coyne

3 joint publications

Khanh T Do

3 joint publications

Lawrence Rubinstein

3 joint publications

James H Doroshow